Breadcrumb

Breadcrumbs

Press Releases

Search Results

Back to Press Releases
Showing 31 - 35 of 35 results.

You searched for : January 2019 to January 2020.

Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Derux ...

Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Positive Metastatic Breast Cancer Post T-DM1 Download the PDF version of...

Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company’s Launch into its Next Growth Ph ...

Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company’s Launch into its Next Growth Phase Download the PDF version of Article February 22, 2019 Dr. Junichi Koga to become new global...

FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartin ...

FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor Download the PDF version of...

Carrie Ann Inaba Partners with Daiichi Sankyo, Inc. to Encourage Americans to “Get Iron Informed”

Carrie Ann Inaba Partners with Daiichi Sankyo, Inc. to Encourage Americans to “Get Iron Informed” Download the PDF version of Article January 29, 2019 Carrie Ann Inaba shares her personal journey...

Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 L ...

Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer Download the PDF version of Article January 14, 2019 DESTINY-Breast04...

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...